Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

Université Laval

$25,000.00

Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site

FY 2020-21

Summary
INTRODUCTION: Topoisomerases (Topo) are important therapeutic targets to treat many cancers. To that end, inhibitors of these enzymes are amongst the most widely used anticancer drugs. For example, Topo I is an enzyme essential to maintain the integrity of our genetic code to avoid introducing harmful mutations while inhibitors of these enzymes induce breakages of this code and death of the cells. I have developed for nearly two years as an independent researcher a new family of promising anticancer drugs referred to “N-phenyl ureidobenzenesulfonates” (PUB-SOs) blocking the activity of this enzyme. PUB-SOs are different from known Topo I inhibitors used in clinic or in development. They are based on a genuine new molecular template easily prepared and modifiable to produce efficient anticancer drugs at low costs. Indeed, I have shown that these compounds block the activity of Topo I by a mechanism that still not identified but different from the drugs used in the clinic. This suggests that they might not be plagued with the same side effects such as diarrhoea and neutropenia and other problems related to their chemical instability and induction of chemoresistance. RESEARCH PROGRAM: My research program aims to locate and study the site where PUB-SOs binds to Topo I. To that end, I will use PUB-SO derivatives and analogs to study that binding site in 3D. Aim 1: Design and preparation of PUB-SOs derivatives and analogs that will be used as “special probes”. Aim 2: Localization of the site on Topo I binding PUB-SOs to block its repairing activity of the genetic code. Aim 3: Study this binding site using tools of biology and pharmacology such as a measure of the effect of new compounds on the repair activity of Topo I and the reproduction of cancer cells. Aim 4: Construction of 3D computer models of Topo I where the PUB-SOs are fixed in order to understand the mechanism of action of these molecules. Aim 5: Design and development of a new test to identify quickly promising compounds inhibiting the activity of Topo I. CONCLUSION: My research program is a unique opportunity to expand on a short-term level our understanding of the tridimensional structure of Topo I when it forms complexes with PUB-SOs. These studies provide a new method for rapid identification of new molecules of interest inhibiting Topo I. Finally, this research program will allow on a longer term to develop new tools for the design and development of the next generations of inhibitors and anticancer drugs. My research program will also offer a stimulating multidisciplinary training for highly qualified personnel in the drug design sector, notably in organic synthesis, molecular pharmacology, cellular biology, mass spectrometry and molecular modeling.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2016-05069
Name nom
Fortin, Sébastien
Department département
Faculté de pharmacie
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2016
Award amount
25000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Bio-organic chemistry
Research subject fr
Chimie bio-organique
Installment
inst:5-6
Partie
2
Nb partie
6
Application title
Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site
Keyword
NSERC
Application summary
INTRODUCTION: Topoisomerases (Topo) are important therapeutic targets to treat many cancers. To that end, inhibitors of these enzymes are amongst the most widely used anticancer drugs. For example, Topo I is an enzyme essential to maintain the integrity of our genetic code to avoid introducing harmful mutations while inhibitors of these enzymes induce breakages of this code and death of the cells. I have developed for nearly two years as an independent researcher a new family of promising anticancer drugs referred to “N-phenyl ureidobenzenesulfonates” (PUB-SOs) blocking the activity of this enzyme. PUB-SOs are different from known Topo I inhibitors used in clinic or in development. They are based on a genuine new molecular template easily prepared and modifiable to produce efficient anticancer drugs at low costs. Indeed, I have shown that these compounds block the activity of Topo I by a mechanism that still not identified but different from the drugs used in the clinic. This suggests that they might not be plagued with the same side effects such as diarrhoea and neutropenia and other problems related to their chemical instability and induction of chemoresistance. RESEARCH PROGRAM: My research program aims to locate and study the site where PUB-SOs binds to Topo I. To that end, I will use PUB-SO derivatives and analogs to study that binding site in 3D. Aim 1: Design and preparation of PUB-SOs derivatives and analogs that will be used as “special probes”. Aim 2: Localization of the site on Topo I binding PUB-SOs to block its repairing activity of the genetic code. Aim 3: Study this binding site using tools of biology and pharmacology such as a measure of the effect of new compounds on the repair activity of Topo I and the reproduction of cancer cells. Aim 4: Construction of 3D computer models of Topo I where the PUB-SOs are fixed in order to understand the mechanism of action of these molecules. Aim 5: Design and development of a new test to identify quickly promising compounds inhibiting the activity of Topo I. CONCLUSION: My research program is a unique opportunity to expand on a short-term level our understanding of the tridimensional structure of Topo I when it forms complexes with PUB-SOs. These studies provide a new method for rapid identification of new molecules of interest inhibiting Topo I. Finally, this research program will allow on a longer term to develop new tools for the design and development of the next generations of inhibitors and anticancer drugs. My research program will also offer a stimulating multidisciplinary training for highly qualified personnel in the drug design sector, notably in organic synthesis, molecular pharmacology, cellular biology, mass spectrometry and molecular modeling.